Logotype for Corline Biomedical

Corline Biomedical (CLBIO) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Corline Biomedical

Q3 2026 earnings summary

16 Nov, 2026

Executive summary

  • Q3 revenue was SEK 2.356M versus SEK 1.305M YoY; lower-than-expected orders drove a temporary sales slowdown and a net loss of SEK 4.774M.

  • Management sees growth from Kardium and new medical-device customers, targeting SEK ~200M revenue in 2030 from Kardium alone.

Financial highlights

  • Jan–Sep revenue was SEK 11.335M versus SEK 5.547M; net loss improved to SEK 8.711M from SEK 9.687M.

  • Q3 operating loss was SEK 4.052M versus SEK 3.359M; net loss was SEK 4.774M versus SEK 3.359M.

  • Q3 operating costs rose to SEK 6.440M from SEK 4.972M, reflecting higher raw-material and personnel costs, including consultants.

  • Cash and cash equivalents were SEK 29.869M at Sep 30, 2026, versus SEK 5.818M a year earlier; cash includes Kardium’s USD 1M loan.

Outlook and guidance

  • FY2026 revenue guidance is SEK 16M and EBITDA guidance is negative SEK 10M; Q4 sales are expected to return to H1 2026 levels.

  • FY2027 guidance is SEK 30M revenue with positive EBITDA, alongside a marginal cost increase versus 2026.

  • SEK ~200M revenue in 2030 is projected from the Kardium relationship alone, based on expected PFA growth and successful Globe product launch.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Corline Biomedical